Date:9/14/2011

vio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.CONTACTS:Investors:

Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia:

Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

'/>"/>

SOURCE Inovio Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
2. Inovio Pharmaceuticals to Present at Investor Conferences
3. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
4. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
5. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
6. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
7. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
9. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C